Research programme: ADAM8 inhibitors - Cancer Research Technology/Medivir

Drug Profile

Research programme: ADAM8 inhibitors - Cancer Research Technology/Medivir

Alternative Names: ADAM8 inhibitors - Medivir

Latest Information Update: 24 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kings College London
  • Developer Cancer Research Technology; Kings College London; Medivir AB; TransMIT Gesellschaft fur Technologietransfer mbH
  • Class Small molecules
  • Mechanism of Action ADAM protein inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Pancreatic cancer

Most Recent Events

  • 17 Nov 2015 Medivir terminates its licence for ADAM8 inhibitors in Sweden
  • 17 Nov 2015 Discontinued for Cancer in Sweden (unspecified route)
  • 17 Nov 2015 Discontinued for Pancreatic cancer in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top